+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study



Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study



Plos One 11(7): E0160337



This study investigated the impact of chronic kidney disease on all-causes and cardiovascular mortality in patients with atrial fibrillation treated with digoxin. All patients with non-valvular atrial fibrillation and/or atrial flutter as hospitalization diagnosis from January 1, 1997 to December 31, 2012 were identified in Danish nationwide administrative registries. Cox proportional hazard model was used to compare the adjusted risk of all-causes and cardiovascular mortality among patients with and without chronic kidney disease and among patients with different chronic kidney disease stages within 180 days and 2 years from the first digoxin prescription. We identified 37,981 patients receiving digoxin; 1884 patients had the diagnosis of chronic kidney disease. Cox regression analysis showed no statistically significant differences in all-causes (Hazard Ratio, HR 0.89; 95% confident interval, CI 0.78-1.03) and cardiovascular mortality (HR 0.88; 95%CI 0.74-1.05) among patients with and without chronic kidney disease within 180 days of follow-up period. No statistically significant differences was found using a 2 years follow-up period neither for all causes mortality (HR 0.90; 95%CI 0.79-1.03), nor for cardiovascular mortality (HR 0.87; 95%CI 0.74-1.02). No statistically significant differences was found comparing patients with and without estimated Glomerular Filtration Rate <30ml/min/1.73m2 and patients with different stages of chronic kidney disease, for all-causes and cardiovascular mortality within 180 days and 2 years from the first digoxin prescription. This study suggest no direct effect of chronic kidney disease and chronic kidney disease stages on all-causes and cardiovascular mortality within both 180 days and 2 years from the first digoxin prescription in patients treatment-naïve with digoxin for non-valvular atrial fibrillation.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057693622

Download citation: RISBibTeXText

PMID: 27467520


Related references

Digoxin use is associated with increased risk of stroke in patients with non-valvular atrial fibrillation--a nationwide population-based cohort study. International Journal of Cardiology 169(2): E26-E27, 2014

Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study. Canadian Journal of Cardiology 30(10): 1190-1195, 2014

The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan. International Journal of Cardiology 265: 83-89, 2018

Association Between Cataract and Risk of Incident Atrial Fibrillation: A Nationwide Population-Based Retrospective Cohort Study. Mayo Clinic Proceedings 92(3): 370-375, 2016

Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden. European Journal of Cancer Prevention 20(4): 326-330, 2011

New-onset Atrial Fibrillation is Associated With Polycystic Kidney Disease: A Nationwide Population-based Cohort Study. Medicine 95(4): E2623, 2016

Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. Bmj Open 8(1): E019638, 2018

Long-term mortality and recurrence in patients treated for colonic diverticulitis with abscess formation: a nationwide register-based cohort study. International Journal of Colorectal Disease 33(4): 431-440, 2018

Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. Journal of the American College of Cardiology 64(23): 2471-2482, 2015

Depression, antidepressants, and the risk of non-valvular atrial fibrillation: A nationwide Danish matched cohort study. European Journal of Preventive Cardiology 2018: 2047487318811184, 2018

Substantial differences in initiation of antithrombotic treatment and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings: a nationwide cohort. European Heart Journal 34(Suppl 1): P529-P529, 2013

Impact of atrial fibrillation on in-hospital mortality of ischemic stroke patients and identification of promoting factors of atrial thrombi - Results from the German nationwide inpatient sample and a single-center retrospective cohort. Medicine 98(4): E14086-E14086, 2019

Effect of radiofrequency catheter ablation for atrial fibrillation on morbidity and mortality: a nationwide cohort study and propensity score analysis. Circulation. Arrhythmia and Electrophysiology 7(1): 76-82, 2014

Digoxin and mortality in atrial fibrillation: a prospective cohort study. European Journal of Clinical Pharmacology 63(10): 959-971, 2007

Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study. Europace 2018, 2018